Le Lézard
Classified in: Health
Subjects: LAW, PLW

Sweegen's Statement Regarding PureCircle Lawsuit


RANCHO SANTA MARGARITA, Calif., Sept. 18, 2018 /CNW/ -- PureCircle filed a complaint in the U.S. District Court for the Central District of California against Sweegen, Inc.  PureCircle claims that Sweegen's Bestevia® Reb-M is infringing PureCircle's patent -- U.S. Patent No. 9,243,273, A Method for Making Rebaudioside M (Reb-M).

SweeGen, Inc. Logo (PRNewsfoto/SweeGen, Inc.)

Sweegen, together with its licensor, has 13 patents granted and over 130 patent applications pending worldwide regarding stevia sweeteners.  This impressive patent portfolio is focused on next generation stevia sweeteners and includes at least 7 novel methods for producing plant-based, non-GMO Reb-M. 

As the innovative provider of next generation stevia sweeteners, Sweegen sells zero-calorie, Non-GMO Project Verified, plant-based Reb-M and Reb-D for use in the food and beverage industry.  These next generation stevia sweeteners enable companies to offer sugar reduced products with the same sugar-like taste we have all grown to enjoy.  Such products include carbonated beverages, juices, yogurts, ice creams, nutritional foods, and confectionery goods such as cookies.  

Sweegen will defend and protect its strong IP position, with deepest respect to innovative Intellectual Property for the benefit of consumers globally.

About Sweegen

Sweegen (OTC: SWEE) is dedicated to the development, production and distribution of zero-calorie stevia sweeteners for the food, beverage and flavor industries. Sweegen's robust product pipeline, intellectual property portfolio, dedicated manufacturing capacity and R&D provide the company its foundation for innovation and delivery of high-quality sweeteners. For more information, please contact [email protected] or visit Sweegen's website www.sweegen.com.

 

SOURCE Sweegen, Inc.


These press releases may also interest you

at 09:10
BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer...

at 09:07
KURU® Footwear, the inventor of heel-first footwear, today unveiled its 2024 Foot Pain Trends Report. Featuring significant industry discoveries and valuable consumer perspectives, KURU's comprehensive and medically reviewed report highlights the...

at 09:05
Personalis, Inc. , a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA...

at 09:05
...

at 09:04
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced today it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million. The announcement comes...

at 09:00
Headlands Research, a leading multinational network of clinical trial sites, today announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse...



News published on and distributed by: